by Garnier T, Mantyla A, Jarvinen T, Lawrence MJ, Brown MB, Croft SL. J Pharm Pharmacol, January 2007, 59(1):41-9.
Summary: As the part of a study to develop buparvaquone (BPQ) formulations for the treatment of cutaneous leishmaniasis, the topical delivery of BPQ and one of its prodrugs from a range of formulations was evaluated. The results confirm that BPQ and its prodrug 3-POM-BPQ can penetrate the skin from several formulations, making them potentially interesting candidates for further investigation of topical formulations using in-vivo models of cutaneous leishmaniasis.
